Core Insights - Aflac Incorporated (AFL) is well-positioned for growth due to strong product demand, high policy persistency, improved underwriting discipline, and effective cost management [1] - The company has a market capitalization of $55.7 billion and offers supplemental health and life insurance products in Japan and the United States [1] - Despite a 3.8% decline in stock value over the past year, Aflac has outperformed the industry average decline of 6.6% [1] Financial Estimates - The Zacks Consensus Estimate for Aflac's 2026 earnings is $7.32 per share, with revenues estimated at $17.2 billion [3] - In the past 30 days, there has been one upward estimate revision for earnings and one downward revision [3] - Aflac has beaten earnings estimates in two of the past four quarters, with an average surprise of 8.3% [3] Growth Drivers - Aflac's revenue growth is supported by strong sales in both the U.S. and Japan, driven by strategic investments and high persistency rates [4] - In Japan, new cancer insurance products like Miraito have contributed to a 16% year-over-year growth in new annualized premium sales in 2025 [4] - In the U.S., premium growth is supported by disciplined underwriting and rising healthcare costs, with new annualized premium sales increasing by 3% year over year in 2025 [5] Strategic Initiatives - Aflac is enhancing its core insurance growth through strategic acquisitions, partnerships, and new product launches [6] - The company is leveraging AI and automation to improve efficiency and sales productivity [6] - Aflac aims to maintain strong capital discipline while enhancing margins and returning capital through dividends and buybacks [7] Key Risks - Operating cash flow has been declining, with a 17.8% drop in 2023, which may limit growth investment flexibility [9] - Aflac's shares trade at a forward P/E of 14.60X, above its five-year median of 12.82X and the industry average of 11.79X, indicating limited near-term upside potential [9]

Aflac Incorporated, a life and health insurer through its subsidiaries in Japan and the U.S., has announced that Aflac Re Bermuda Ltd. (Aflac Re) has agreed with Japan Post Insurance Co., Ltd. to reinsure a block of whole life annuities through coinsurance, effective 31st March 2026.This marks Aflac Re’s first reinsurance transaction with an external party. Japan Post Insurance will continue to service and administer the policies.Max Brodén, Senior Executive Vice President, Chief Financial Officer of Aflac ...

Core Insights - Aflac Re Bermuda Ltd. has entered into a reinsurance agreement with Japan Post Insurance Company to reinsure a block of whole life annuities through coinsurance, effective March 31, 2026 [1][2] - This transaction is significant as it marks Aflac Re's first reinsurance deal with an external party, enhancing its strategic partnership with Japan Post Insurance [2] Company Overview - Aflac Incorporated is a leading life and health insurer with a strong presence in both Japan and the U.S., recognized as the No. 1 provider of supplemental health insurance in the U.S. and the leading provider of cancer and medical insurance in Japan [2] - The company has been acknowledged for its ethical practices, being listed among the World's Most Ethical Companies for 20 consecutive years and Fortune's World's Most Admired Companies for 25 years [2] Strategic Goals - Aflac aims to create shared value for policyholders and shareholders through this partnership with Japan Post Insurance, while also looking to support other Japanese life insurers in risk reduction and capital management [2]

Group 1: Company Overview - Aflac Incorporated (NYSE:AFL) provides financial protection through its subsidiaries in the United States and Japan, focusing on supplemental health and life insurance products [5]. Group 2: Analyst Coverage and Market Outlook - Keefe Bruyette & Woods re-initiated coverage of Aflac with a Market Perform rating and a price target of $113, noting a mixed fundamental picture in the life insurance sector [2]. - The analyst highlighted improvements in free cash flow conversion and reduced liability tail risk, but also pointed out rising competition and increasing balance sheet complexity [2]. Group 3: Financial Guidance and Projections - For Aflac Japan, underlying earned premiums are expected to decline by about 1% to 2% in 2026, with an expense ratio projected between 20% and 23% and a benefit ratio between 60% and 63% [3]. - In the US segment, net earned premium growth is expected at the lower end of the 3% to 6% range, with a benefit ratio projected between 48% and 52% and an expense ratio between 36% and 39% [4].

Core Insights - Aflac Incorporated (AFL) has launched a hybrid worksite benefit that combines term life insurance with long-term care (LTC) coverage, addressing the rising costs of care and enhancing consumer financial security [1][5]. Product Features - The new rider allows for an extended LTC benefit period and restores the full face value of the life insurance policy even after LTC funds have been utilized, along with an optional inflation protection feature [2][9]. - It includes a fund that grows annually to increase the overall value of the LTC benefit, offering flexible payment options such as lump-sum or periodic payments [3]. - Coverage is portable, enabling policyholders to retain benefits after leaving their employer, and full LTC benefits can be accessed regardless of the care setting [4][9]. Market Context - The introduction of this product is timely, as the cost of LTC is rising, creating challenges for an aging U.S. population and increasing the demand for comprehensive life and LTC planning [5]. - Aflac's new offering is expected to enhance customer satisfaction, attract new policyholders, and improve retention among existing customers, potentially leading to increased premium income [6]. Financial Performance - In 2025, Aflac's U.S. unit generated net earned premiums of $6 billion, reflecting a year-over-year growth of 2.9%, with total new sales increasing by 3% during the same period [7]. - Net earned premiums are projected to grow at the lower end of the 3-6% range in 2026 for the U.S. business [7]. Share Price and Industry Comparison - Aflac's shares have declined by 2.8% over the past year, compared to a 4.6% decline in the industry [8].

Core Insights - Aflac has introduced a new long-term care rider as part of its Group Life Term to 120 product, aimed at providing financial protection against rising long-term care costs for aging Americans [1][5] - The product is designed to meet the growing need for life insurance and long-term care planning as the U.S. population ages, with projections indicating that 1 in 6 Americans will be over 60 by 2030 [2][3] Product Features - The new long-term care rider offers flexibility, allowing insured individuals to choose between home-based care, facility-based care, or care from family and friends, thus catering to personal preferences [3][4] - Key benefits include optional extensions of the LTC benefit period, restoration of life insurance amounts after LTC funding, inflation protection, and various payment options [6][4] Market Context - The introduction of this product aligns with the demographic shift known as the "Silver Tsunami," where baby boomers are reaching retirement age, increasing the demand for long-term care solutions [2][3] - Aflac's initiative is positioned to help employers attract and retain talent by offering benefits that provide security and choice to employees [4][5]

Core Insights - Aflac has been recognized as a World's Most Ethical Company for 20 consecutive years, making it the only insurance company to achieve this distinction since the award's inception in 2007 [1][2][4] Company Recognition - Aflac's Chairman and CEO, Dan Amos, expressed that this recognition serves as a consistent approval of the ethical actions of the company's employees and leaders, highlighting the correlation between ethical conduct and better company performance [2][3] - In 2026, a total of 138 companies were recognized as honorees, spanning 17 countries and 40 industries, with only six organizations being recognized for 20 times [4] Community Commitment - Aflac has a long-standing commitment to community support, notably contributing nearly $200 million to the Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta since 1995 [2] Ethical Standards - The assessment for the World's Most Ethical Companies is based on Ethisphere's proprietary Ethics Quotient®, which evaluates companies on over 240 documented proof points related to ethics and compliance practices [5]

Core Viewpoint - Aflac's recent earnings report showed mixed results, with adjusted earnings per share missing estimates while revenues declined year over year, raising questions about the company's future performance leading up to the next earnings release [2][3]. Financial Performance - Aflac reported Q4 2025 adjusted EPS of $1.57, missing the Zacks Consensus Estimate by 8.2%, but showing a year-over-year improvement of 0.6% [3]. - Adjusted revenues for the quarter totaled $4.9 billion, a decline of 9.9% year over year, although it beat the consensus mark by 8.7% [3]. - Adjusted net investment income decreased by 4.4% year over year to $920 million [5]. - Total acquisition and operating expenses increased by 3.5% year over year to $1.4 billion [5]. Segment Performance - Aflac Japan's adjusted revenues fell 3.6% year over year to $2.3 billion, missing the consensus estimate [6]. - In Aflac U.S., adjusted revenues grew 3.3% year over year to $1.73 billion but also missed the consensus estimate [7]. Full-Year Update - For the full year 2025, adjusted EPS improved by 3.5% year over year to $7.46, while total revenues fell by 9.3% to $17.2 billion [9]. Financial Position - As of December 31, 2025, Aflac had total investments and cash of $103.8 billion, a decrease of 1.3% from the previous year [10]. - Adjusted debt increased by 7.1% to $7.7 billion, with total shareholders' equity rising by 13% to $29.5 billion [11]. Capital Deployment - Aflac repurchased 7.2 million shares for $800 million in Q4 2025 and announced a quarterly dividend increase of 5.2% to 61 cents per share [13]. 2026 Outlook - Aflac anticipates a benefit ratio of 60-63% for the Japan unit and 48-52% for the U.S. unit in 2026 [14]. - The company expects a year-over-year decline of 1-2% in underlying earned premiums for the Japan unit, while the U.S. unit is projected to grow at the lower end of the 3-6% range [14]. Market Sentiment - Since the earnings release, there has been an upward trend in estimates for Aflac, although the stock currently holds a Zacks Rank 4 (Sell), indicating expectations of below-average returns in the near term [16][18].

Company Overview - Aflac Incorporated (AFL) is an insurance company providing supplemental financial-protection products primarily in the U.S. and Japan, with a market capitalization of $58.06 billion [1] Stock Performance - Aflac's shares reached a 52-week high of $119.32 on February 5, but are currently down 5.7% from that peak, reflecting a slow but steady growth profile [2] - Over the past three months, Aflac's stock has gained 3%, outperforming the Dow Jones Industrial Average, which is up 1.9% during the same period [2] - In the past 52 weeks, Aflac's stock has increased by 4.5%, while the Dow Jones index has risen by 14.6% [3] - Year-to-date, Aflac's stock has increased by 2%, compared to the Dow's gain of 1.4% [3] - The stock has been trading above its 50-day moving average since late January and above its 200-day moving average since late October [3] Financial Results - Aflac reported a 9.9% year-over-year decline in quarterly revenue for fiscal Q4 2025, totaling $4.87 billion, which was higher than analysts' expectations, resulting in a 3.4% intraday stock gain on February 5 [4] Strategic Focus - For 2026, Aflac aims to focus on third-sector products in the Aflac Japan segment to attract younger customers, while in the U.S. segment, the focus is on profitable growth through strong underwriting discipline and improved agent productivity [5] Market Comparison - Compared to MetLife, which has dropped 10.1% over the past 52 weeks and 7.1% year-to-date, Aflac has shown clear outperformance [6] - Aflac's stock has a consensus rating of "Hold" from 15 analysts, with a mean price target of $112.38, indicating flat performance from current levels, while the highest price target of $130 suggests a potential upside of 15.6% [6]

Core Insights - Aflac Incorporated (NYSE:AFL) is recognized as one of the 14 Best Affordable Dividend Stocks to buy according to analysts [1] - Wells Fargo analyst Elyse Greenspan raised the price target for Aflac to $118 from $109 while maintaining an Equal Weight rating, reflecting a shift in valuation approach and updated EPS estimates for 2027 and 2028 [2] Financial Performance - In Q4 2025, Aflac reported net earnings of $2.64 per diluted share and adjusted earnings of $1.57 per diluted share, indicating strong financial performance [3] - Aflac Japan experienced a sales increase of 15.7% in Q4 and 16% for the full year, driven by the success of the Miraito cancer insurance product, which saw a 35.6% sales increase [3] - Aflac U.S. generated nearly $1.6 billion in new sales in 2025, with over one-third of that amount coming in Q4 [4] Strategic Initiatives - The company emphasized a focus on profitable growth, careful underwriting, and disciplined expense management, with a premium persistency rate of 79.2% [4] - Aflac's board approved a 5.2% dividend increase for Q1 2026, and in 2025, the company returned significant capital to shareholders, including $3.5 billion for share repurchases and $1.2 billion in dividends [4] Business Overview - Aflac Incorporated provides supplemental health and life insurance in the U.S. and Japan, offering financial protection to policyholders [5]